The primary objective of this study is to determine the effect of enzalutamide and dutasteride on the time to prostatic-specific antigen progression in patients aged 65 or older receiving this combination as first line treatment for systemic prostate cancer.~To determine the safety and toxicities of the study drug combination.~To determine the time to prostatic-specific antigen nadir from the start of study treatment and to evaluate the absolute prostatic-specific antigen nadir as a result of the study drug combination
Determine the effect of enzalutamide and dutasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.